VA
KLRS

Verdad Advisers’s Kalaris Therapeutics KLRS Stock Holding History

Verdad Advisers’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$327K Buy
+80,297
New +$417K 0.31% 110

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verdad Advisers's KLRS Position: Q2 2026 in Review

Verdad Advisers opened a new position in Kalaris Therapeutics (KLRS) in Q2 2026: 80,297 shares worth $327K. The stake represents 0.31% of the portfolio and ranks #110 among its holdings.

57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Verdad Advisers held 80,297 shares of Kalaris Therapeutics worth $327K as of Q2 2026.
  • Kalaris Therapeutics was a new Verdad Advisers position in Q2 2026.
  • Kalaris Therapeutics made up 0.31% of Verdad Advisers's portfolio in Q2 2026, its #110 holding.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.